cyclinE CDK2 in uterine smooth muscle tumors.docVIP

 PAGE \* MERGEFORMAT 3 cyclinE CDK2 in uterine smooth muscle tumors [Keywords:] cyclinE; CDK2; uterine smooth muscle tumors Uterine smooth muscle tumors (uterine smooth muscle tumors, USMTs) is the most common tumors of women. Cyclin (cyclinE) is a G1 phase cyclins, and cyclin-dependent kinase 2 (CDK2) in the G1 end of combination play a role in promoting cell to enter S phase. In recent years, studies in a variety of tumors found in cyclinE, CDK2 expression of abnormal, but its USMTs the study, the domestic literature has not been reported. Proliferating cell nuclear antigen (PCNA) to reflect the cells, particularly cancer cells, an indicator of proliferative activity. In this study immunohistochemical methods to be adopted to explore cyclinE, CDK2, and PCNA expression in USMTs and clinical significance. 1 Data and methods 1.1 The clinical data of selected, Huazhong University of Science and Technology, Tongji Hospital, Tongji Medical College, Department of Pathology, in July 1992 ~ October 2004 archives by USMTs the surgical hysterectomy specimens of 75 cases of the wax block, in which benign uterine leiomyoma (usual leiomyoma, UL n = 35), borderline uterine smooth muscle tumors (borderline leiomyoma, BLM) 22 cases of uterine sarcoma (leiomyosarcoma, LMS) 18 Li. Another take on the operating room and normal uterine smooth muscle tissues (Myometrium, M) 20 cases, 4% paraformaldehyde fixed, paraffin-embedded conventional treatment. 1.2 Reagents cyclinE mouse anti-human monoclonal antibody, the working concentration of 1:100; mouse anti-human CDK2 monoclonal antibody, the working concentration of 1:50; mouse anti-human PCNA monoclonal antibody, the working concentration of 1:50, both the United States Santa Cruz Inc. products, purchased in Beijing Zhongshan Biological Engineering Company. SP kit and DAB kit were Zymed chromogenic products. 1.3 Methods The immunohistochemical SP method to detect the UL group, BLM group, LMS group and M group cyclinE, CDK2